Talacotuzumab with decitabine for acute myeloid leukaemia
Talacotuzumab is a new drug to treat acute myeloid leukaemia, a rare and aggressive type of cancer that affects the way blood cells develop. This leads to an increased risk of infection, as well as symptoms such as anaemia and bruising. Acute myeloid leukaemia is quickly fatal if not treated. Talacotuzumab is delivered straight into the blood and is used in combination with another drug called decitabine. Talacotuzumab with decitabine may prevent the disease from returning by ensuring all cancer cells are eliminated.